8S6I | pdb_00008s6i

Crystal structure of the human CDKL2 kinase domain with Compound 9


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.72 Å
  • R-Value Free: 
    0.222 (Depositor), 0.221 (DCC) 
  • R-Value Work: 
    0.205 (Depositor), 0.204 (DCC) 
  • R-Value Observed: 
    0.205 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.

Bashore, F.M.Min, S.M.Chen, X.Howell, S.Rinderle, C.H.Morel, G.Silvaroli, J.A.Wells, C.I.Bunnell, B.A.Drewry, D.H.Pabla, N.S.Ultanir, S.K.Bullock, A.N.Axtman, A.D.

(2024) ACS Med Chem Lett 15: 1325-1333

  • DOI: https://doi.org/10.1021/acsmedchemlett.4c00219
  • Primary Citation of Related Structures:  
    8S6I

  • PubMed Abstract: 

    Acylaminoindazole-based inhibitors of CDKL2 were identified via analyses of cell-free binding and selectivity data. Compound 9 was selected as a CDKL2 chemical probe based on its potent inhibition of CDKL2 enzymatic activity, engagement of CDKL2 in cells, and excellent kinome-wide selectivity, especially when used in cells. Compound 16 was designed as a negative control to be used alongside compound 9 in experiments to interrogate CDKL2-mediated biology. A solved cocrystal structure of compound 9 bound to CDKL2 highlighted key interactions it makes within its ATP-binding site. Inhibition of downstream phosphorylation of EB2, a CDKL2 substrate, in rat primary neurons provided evidence that engagement of CDKL2 by compound 9 in cells resulted in inhibition of its activity. When used at relevant concentrations, compound 9 does not impact the viability of rat primary neurons or certain breast cancer cells nor elicit consistent changes in the expression of proteins involved in epithelial-mesenchymal transition.


  • Organizational Affiliation

    Structural Genomics Consortium (SGC), UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Cyclin-dependent kinase-like 2331Homo sapiensMutation(s): 0 
Gene Names: CDKL2
EC: 2.7.11.22
UniProt & NIH Common Fund Data Resources
Find proteins for Q92772 (Homo sapiens)
Explore Q92772 
Go to UniProtKB:  Q92772
PHAROS:  Q92772
GTEx:  ENSG00000138769 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ92772
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.72 Å
  • R-Value Free:  0.222 (Depositor), 0.221 (DCC) 
  • R-Value Work:  0.205 (Depositor), 0.204 (DCC) 
  • R-Value Observed: 0.205 (Depositor) 
Space Group: P 32
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 58.093α = 90
b = 58.093β = 90
c = 104.261γ = 120
Software Package:
Software NamePurpose
PHENIXrefinement
xia2.multiplexdata reduction
DIALSdata scaling
PHENIXphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Innovative Medicines InitiativeSwitzerland875510

Revision History  (Full details and data files)

  • Version 1.0: 2025-02-26
    Type: Initial release